Walgreens Boots Q3 2023 earnings on deck, what to expect
jetcityimage/iStock Editorial via Getty Images

Pharmacy chain Walgreens Boots (NASDAQ:WBA) is scheduled to announce Q3 earnings results on Tuesday, June 27th, before market open.
The consensus EPS estimate is $1.07 and the consensus revenue estimate is $34.12 billion.
Over the last 2 years, WBA has beaten EPS estimates 100% of the time and has beaten revenue estimates 100% of the time.

Over the last 3 months, EPS estimates have seen 0 upward revisions and 12 downward. Revenue estimates have seen 5 upward revisions and 4 downward.
The company on March 28 reported Q2 Non-GAAP EPS of $1.16, beating estimates by 5 cents. Revenue of $34.9 billion was up 7.6% from last year and ahead of consensus by at least $1.34 billion.
WBA has a Quant rating of "HOLD", with a 3.05 rating score.
WBA has an industry ranking of 1 out of 3 among drug retail stocks, as per SA's Quant ranking.
Wall Street analysts and Seeking Alpha authors rate the WBA stock "HOLD".
WBA stock fell 26.3% in 2022, while the benchmark S&P 500 index slipped nearly 20% for the year.
Stock is down 13.1% so far this year as of Friday's close.

 Recent analysis on WBA:

"Walgreens Boots Alliance has been disappointing in price for almost eight years, but analysts give it a 5-star undervaluation rating and a suggested cheap buy price of $33.60. Walgreens' future potential seems to point to a better 2024 with synergies from its acquisitions starting to come to fruition and growth expected," writes RoseNose, leader of "Macro Trading Factory" Investing Group on Seeking Alpha.

Walgreens: A Dividend Aristocrat Paying 6.2% With Turnaround Potential by Bill Zettler, leader of the Investing Group "Turnaround Stock Advisory" on Seeking Alpha.

Walgreens Earnings Preview: Running To Stand Still by Brian Gilmartin.

Recent news on WBA:

Walgreens announced a partnership with biotech Freenome to jointly conduct clinical studies for the latterâs blood-based tests for early cancer detection in a multi-year partnership.
Earlier this month, the company agreed to pay $500 million to the State of New Mexico to settle litigation stemming from how it handled prescriptions for opioids in that state.

Teva, Walgreens, CVS, AbbVie to pay $17.3B in national opioid settlement.